急性冠状动脉综合征介入治疗应用替罗非班致极重度血小板减少症

Tirofiban-associated acute thrombocytopenia in acute coronary syndromes patients treated with percutaneous coronary intervention

目的探讨替罗非班诱导的极重度血小板减少症的特点、防治策略以及临床药师在其中应发挥的作用。方法临床药师以1例急性冠状动脉综合征介入治疗的患者为例,分析应用替罗非班导致极重度血小板减少的原因和发生血小板减少症的治疗方法以及临床药师实施药学监护的切入点。结果与讨论临床药师协助临床医师判断血小板减少症发生的原因,及时停用替罗非班,使得患者血小板逐渐恢复,准予出院。

Objective To explore the characteristics and prevention strategy of thrombocytopenia induced by tirofiban,and the role of clinical pharmacists in this case. Methods According to the characteristics of this case,we discussed the reason and treatment of thrombocytopenia induced by tirofiban and the pharmaceutical care points of patients with the thrombocytopenia. Results and Conclusion Clinical pharmacist assisted clinician to judge the reason of thrombocytopenia occurence,the tirofiban was stopped timely,and finally made the patients platelet recovery gradually as out of the hospital.